Progress in Molecular Biology and Translational Science, Volume 167, provides the most topical, informative and exciting monographs available on a wide variety of research topics related to Models and Biological Targets in Drug Discovery for Attention Deficit Hyperactivity Disorder, Novel Targets for Parkinson-Depression Co-morbidity. Utility of Cannabidiol (CBD) in Neuropsychiatric Disorders: A Short Review of the Recent Pre-clinical and Clinical Findings, The Many Sides of Microglia in Alcohol Use Disorders, Stress, Anxiety, Molecular Targets and More, Calcineurin Signaling in Psychiatric Disorders, Emerging Evidence for the Role of Pituitary Adenylate Cyclase- Activating Peptide (PACAP) in Neuropsychiatric Disorders, and more.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Shafiqur Rahman, Ph.D. is Professor of Pharmacology in the Department of Pharmaceutical Sciences at South Dakota State University (SDSU) in Brookings, USA. He received his Ph.D. in Neuropharmacology from the Memorial University of Newfoundland, Canada. Dr. Rahman completed his post-doctoral fellowship in the Department of Psychiatry from Indiana University School of Medicine in Indianapolis in USA. Prior to joining SDSU, he worked as research scientist and faculty at the University of Kentucky in Lexington, USA and the University of Toronto, Canada.
Dr. Rahman's research focus is drug discovery in neuropharmacology, i.e. the development of novel therapeutic candidates for the treatment of alcohol/nicotine addiction and neuropsychiatric disorders using animal models. His research resulted in over 200 publications/presentations, including peer-reviewed scientific articles, reviews, book chapters, meeting abstracts and seminar presentations. Dr. Rahman served on numerous scientific review panels and editorial boards of several scientific Journals. He has authored or edited multiple books or Journals in drug addiction and neuropharmacology field. Dr. Rahman is also affiliated with a number of professional organizations, including Society for Neuroscience and American Society for Pharmacology and Experimental Therapeutics.